接受全身抗肿瘤治疗的癌症患者静脉血栓栓塞风险评估模型的验证
这项前瞻性观察队列研究纳入806例开始当代全身抗肿瘤治疗的癌症患者,评估6种外部验证过的静脉血栓栓塞风险评估模型的表现。6个月内91例发生静脉血栓栓塞,累积发生率11.2%(95%CI 9.0-13.3)。各模型区分度从差到中等,CAT评分表现最佳(c-statistic 0.65,95%CI 0.62-0.67),COMPASS-CAT最低(0.50,95%CI 0.47-0.53)。
要点
- 6个月内静脉血栓栓塞累积发生率为11.2%(95%CI 9.0-13.3)
- CAT评分区分度最佳,c-statistic为0.65(95%CI 0.62-0.67)
- COMPASS-CAT评分区分度最低,c-statistic为0.50(95%CI 0.47-0.53)
核心结论
- 在当代接受全身抗肿瘤治疗的癌症患者队列中,所评估的风险评估模型整体区分度从差到中等,CAT评分在所有评估评分中表现最佳。
研究设计与样本
- 前瞻性观察队列研究,纳入806例开始当代全身抗肿瘤治疗的癌症患者,女性占49.5%,中位年龄61岁(四分位距53-69)。
主要发现
- 6个月观察期内91例发生静脉血栓栓塞,累积发生率11.2%(95%CI 9.0-13.3)。
- 各模型c-statistic:Khorana评分0.53(95%CI 0.50-0.56),PROTECHT 0.58(95%CI 0.56-0.61),CONKO 0.54(95%CI 0.51-0.57),COMPASS-CAT 0.50(95%CI 0.47-0.53),CAT评分0.65(95%CI 0.62-0.67),EHR-CAT 0.55(95%CI 0.52-0.57)。
关键数值与推荐
- 最常见肿瘤类型为肺癌21.8%、乳腺癌10.8%、胰腺癌10.3%。
- 研究入组时启动的抗肿瘤治疗包括化疗48.3%、化疗联合免疫检查点抑制剂16.6%、免疫检查点抑制剂单药15.4%、靶向药物19.7%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cancer increases the risk of venous thromboembolism (VTE). To identify patients with cancer at high VTE risk who might benefit from primary thromboprophylaxis, several risk assessment models (RAMs) have been developed. The evolution of anticancer treatment, including the implementation of targeted and immunotherapeutic agents, might affect VTE risk and risk prediction. Therefore, we aimed to evaluate the performance of 6 externally validated RAMs (Khorana score, PROTECHT, CONKO, COMPASS-CAT, CATScore, and EHR-CAT) in a prospective observational cohort study of patients with cancer initiating contemporary systemic anticancer therapies. Eight hundred six patients (49.5% female) with a median age of 61 years (interquartile range, 53-69) were included. The most common cancer types were lung (21.8%), breast (10.8%), and pancreatic (10.3%). Anticancer therapies initiated at study inclusion included chemotherapy (48.3%), a combination of chemotherapy and immune checkpoint inhibitor (ICI; 16.6%), ICI monotherapy (15.4%), and targeted agents (19.7%). During an observation period of 6 months, 91 patients experienced a VTE (cumulative incidence, 11.2%; 95% confidence interval [CI], 9.0-13.3). The discriminatory performance of the RAMs varied, with the best c-statistic seen with the CAT Score, whereas the COMPASS-CAT score showed the lowest area under the curve value (c-statistics: Khorana score, 0.53 [95% CI, 0.50-0.56]; PROTECHT, 0.58 [95% CI, 0.56-0.61]; CONKO, 0.54 [95% CI, 0.51-0.57]; COMPASS-CAT, 0.50 [95% CI, 0.47-0.53]; CAT Score, 0.65 [95% CI, 0.62-0.67]; EHR-CAT, 0.55 [95% CI, 0.52-0.57]). Overall, we observed a poor to modest discriminatory performance of the RAMs in our contemporary cohort of patients with cancer, with the CAT Score performing best among all evaluated scores.
引用
- Vladić N, Englisch C, Berger JM, et al. Validation of risk assessment models for venous thromboembolism in patients with cancer receiving systemic therapies. Blood Adv. 2025. PMID: 40117478. doi:10.1182/bloodadvances.2025016044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。